Close

Refine your search

UEF Neurodegeneration - Myohanen Lab´s Profile image

UEF Neurodegeneration - Myohanen Lab

Research group
02.08.2021 -
School of Pharmacy, Faculty of Health Sciences
Information People

Leaders

    The current treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases, is mainly symptomatic. However, the neuronal death progresses and leads to more severe symptoms where current medications are powerless. Therefore, UEF Neurodegeneration lab has strong focus on developing a disease-modifying therapy to stop or delay the disease progression.

    There are several common toxic mechanisms among neurodegenerative diseases. Our aim is to find and identify drug targets that can be used to multitarget on several toxic mechanisms via one target. One such target is PREP enzyme that we have studied over a decade, and by using PREP inhibitors, we have gained excellent results in the models of Parkinson’s and Huntington’s diseases, and in multiple system atrophy (MSA). Our most recent focus is the most common neurodegenerative diseases, Alzheimer’s disease.

    In addition to pharmacological research (compound testing on different disease models), we collaborate actively with experts on medicinal chemisry (Dr. Erik Wallén), molecular modelling (Dr. Maija Lahtela-Kakkonen, Dr. Katarzyna Walczewska-Szewc) and protein structural studies (Prof. Juha Rouvinen/Janne Jänis).

    News

    Cooperation

    Keywords

    Alzheimer's disease drug development neurodegenerative diseases Parkinson's disease

    Leaders

      Professors

        Post-doctoral Researchers

          Technicians

          Other group members

          • M.Sc. Henri Pätsi (Helsinki)
          • Dr. Erik Wallén (Helsinki)
          • Dr. Rui Yang